ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
다발성 골수종 치료제 시장 규모는 2025년 353억 달러에서 2034년에는 653억 8,000만 달러에 달할 것으로 예측되며, 2026년부터 2034년까지 CAGR 7.09%로 성장할 전망입니다.
다발성 골수종 치료제 시장은 다발성 골수종 발생률 증가와 치료법의 지속적인 발전에 힘입어 견조한 성장세를 보이고 있습니다. 골수에서 비정상적인 형질세포의 증식을 특징으로 하는 혈액암의 일종인 다발성 골수종은 진단과 관리 측면에서 큰 문제를 야기합니다. 의료 서비스 제공자들이 환자의 치료 결과를 개선하고자 하는 가운데, 단클론항체, 프로테아좀 억제제, 면역조절제 등 혁신적인 치료제에 대한 수요가 급증하고 있습니다. 임상의들이 환자 개개인의 프로파일에 맞는 치료 계획을 세우려고 노력하는 가운데, 맞춤형 의료와 표적치료에 대한 관심이 높아지면서 시장을 더욱 촉진하고 있습니다.
기술 발전은 다발성 골수종 치료제 시장을 형성하는 데 있어 매우 중요한 역할을 하고 있으며, 신약 개발 기술과 약물전달 시스템의 혁신이 치료 효과와 안전성 향상에 기여하고 있습니다. CAR T 세포 치료와 이중특이성항체의 등장은 다발성 골수종 치료의 새로운 영역을 개척하여 재발 및 난치성 질환 환자에게 유망한 결과를 가져다주고 있습니다. 또한, 동반진단의 통합으로 의료진은 특정 치료법으로부터 가장 큰 혜택을 받을 가능성이 높은 환자를 식별할 수 있어 치료 결과를 최적화할 수 있습니다. 시장이 계속 진화하는 가운데, 치료제의 진보를 위한 연구개발을 우선시하는 기업이 경쟁 우위를 점할 가능성이 높습니다.
또한, 다발성 골수종 치료제 시장은 규제 동향과 새로운 치료법에 대한 임상적 검증의 필요성에 의해 점점 더 많은 영향을 받고 있습니다. 의료 시스템이 증거에 기반한 관행을 채택함에 따라, 엄격한 임상시험을 통해 안전성과 유효성을 입증한 치료제에 대한 수요는 계속 증가할 것입니다. 이러한 추세는 새로운 치료법 조합을 찾고 기존 치료법을 개선하기 위한 연구 이니셔티브에 대한 투자를 촉진하고 있습니다. 또한, 환자 중심 치료에 대한 관심 증가와 치료 결정에 있어 삶의 질에 대한 중요성이 다발성 골수종 치료제의 시장 환경을 형성하고 있습니다. 제품 개발을 임상적 요구와 일치시키고, 환자 결과 개선에 있어 자사 솔루션의 가치를 입증할 수 있는 기업들은 이 역동적인 시장에서 성공할 수 있는 좋은 위치에 있습니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 변수, 동향, 프레임워크
제4장 세계의 다발성 골수종 치료제 시장 : 치료 유형별
제5장 세계의 다발성 골수종 치료제 시장 : 투여 경로별
제6장 세계의 다발성 골수종 치료제 시장 : 질환 유형별
제7장 세계의 다발성 골수종 치료제 시장 : 최종사용별
제8장 세계의 다발성 골수종 치료제 시장 : 지역별
제9장 경쟁 구도
제10장 기업 개요
KSM
영문 목차
영문목차
The Multiple Myeloma Therapeutics Market size is expected to reach USD 65.38 Billion in 2034 from USD 35.30 Billion (2025) growing at a CAGR of 7.09% during 2026-2034.
The Multiple Myeloma Therapeutics market is experiencing robust growth, driven by the increasing incidence of multiple myeloma and the ongoing advancements in treatment options. Multiple myeloma, a type of blood cancer characterized by the proliferation of abnormal plasma cells in the bone marrow, presents significant challenges in terms of diagnosis and management. As healthcare providers seek to improve patient outcomes, the demand for innovative therapeutics, including monoclonal antibodies, proteasome inhibitors, and immunomodulatory drugs, is surging. The growing emphasis on personalized medicine and targeted therapies is further propelling the market, as clinicians aim to tailor treatment regimens to individual patient profiles.
Technological advancements are playing a pivotal role in shaping the Multiple Myeloma Therapeutics market, with innovations in drug development and delivery systems enhancing treatment efficacy and safety. The emergence of CAR T-cell therapy and bispecific antibodies represents a new frontier in multiple myeloma treatment, offering promising results for patients with relapsed or refractory disease. Additionally, the integration of companion diagnostics is enabling healthcare providers to identify patients who are most likely to benefit from specific therapies, thereby optimizing treatment outcomes. As the market continues to evolve, companies that prioritize research and development to advance their therapeutic offerings will likely gain a competitive edge.
Moreover, the Multiple Myeloma Therapeutics market is increasingly influenced by regulatory developments and the need for clinical validation of new therapies. As healthcare systems adopt evidence-based practices, the demand for therapeutics that demonstrate safety and efficacy through rigorous clinical trials will continue to rise. This trend is driving investment in research initiatives aimed at exploring novel treatment combinations and improving existing therapies. Furthermore, the growing focus on patient-centric care and the importance of quality of life in treatment decisions are shaping the landscape of multiple myeloma therapeutics. Companies that align their product development with clinical needs and demonstrate the value of their solutions in improving patient outcomes will be well-positioned to thrive in this dynamic market.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
MARKET SEGMENTATION
By Treatment Type
Chemotherapy
Targeted therapy
Immunomodulating agents
Stem cell transplantation
Radiation therapy
By Route of Administration
Oral
Parenteral
By Disease Type
Active multiple myeloma
Smoldering multiple myeloma
By End-use
Hospitals
Specialty clinics
Homecare settings
Other
COMPANIES PROFILED
Cleveland Clinic, DanaFarber Cancer Institute, Inc, Mayo Foundation for Medical Education and Research MFMER, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, AbbVie Inc, Amgen Inc, BristolMyers Squibb Company, Glenmark Pharmaceuticals Ltd, Johnson Johnson Services, Inc, Merck Co, Inc, Novartis AG, Sanofi SA
We can customise the report as per your requriements
TABLE OF CONTENTS
Chapter 1. PREFACE
1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1 Information Analysis
1.3.2 Market Formulation & Data Visualization
1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
3.4.1 Standards & Compliance
3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
3.5.1 Market Drivers
3.5.2 Market Restraints
3.5.3 Market Opportunities
3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis
Chapter 4. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)
4.1. Market Analysis, Insights and Forecast Treatment Type
4.2. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Targeted therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Immunomodulating agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.5. Stem cell transplantation Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.6. Radiation therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)
5.1. Market Analysis, Insights and Forecast Route Of Administration
5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET: BY DISEASE TYPE 2022-2034 (USD MN)
6.1. Market Analysis, Insights and Forecast Disease Type
6.2. Active multiple myeloma Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Smoldering multiple myeloma Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET: BY END-USE 2022-2034 (USD MN)
7.1. Market Analysis, Insights and Forecast End-use
7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.3. Specialty clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.4. Homecare settings Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.5. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 8. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)
8.1. Regional Outlook
8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.2.1 By Treatment Type
8.2.2 By Route Of Administration
8.2.3 By Disease Type
8.2.4 By End-use
8.2.5 United States
8.2.6 Canada
8.2.7 Mexico
8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.3.1 By Treatment Type
8.3.2 By Route Of Administration
8.3.3 By Disease Type
8.3.4 By End-use
8.3.5 United Kingdom
8.3.6 France
8.3.7 Germany
8.3.8 Italy
8.3.9 Russia
8.3.10 Rest Of Europe
8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.4.1 By Treatment Type
8.4.2 By Route Of Administration
8.4.3 By Disease Type
8.4.4 By End-use
8.4.5 India
8.4.6 Japan
8.4.7 South Korea
8.4.8 Australia
8.4.9 South East Asia
8.4.10 Rest Of Asia Pacific
8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.5.1 By Treatment Type
8.5.2 By Route Of Administration
8.5.3 By Disease Type
8.5.4 By End-use
8.5.5 Brazil
8.5.6 Argentina
8.5.7 Peru
8.5.8 Chile
8.5.9 South East Asia
8.5.10 Rest of Latin America
8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.6.1 By Treatment Type
8.6.2 By Route Of Administration
8.6.3 By Disease Type
8.6.4 By End-use
8.6.5 Saudi Arabia
8.6.6 UAE
8.6.7 Israel
8.6.8 South Africa
8.6.9 Rest of the Middle East And Africa
Chapter 9. COMPETITIVE LANDSCAPE
9.1. Recent Developments
9.2. Company Categorization
9.3. Supply Chain & Channel Partners (based on availability)
9.4. Market Share & Positioning Analysis (based on availability)
9.5. Vendor Landscape (based on availability)
9.6. Strategy Mapping
Chapter 10. COMPANY PROFILES OF GLOBAL MULTIPLE MYELOMA THERAPEUTICS INDUSTRY
10.1. Top Companies Market Share Analysis
10.2. Company Profiles
10.2.1 Cleveland Clinic
10.2.2 Dana-Farber Cancer InstituteInc
10.2.3 Mayo Foundation For Medical Education And Research (MFMER)
